Skip to main content

Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.

Publication ,  Journal Article
Mainiero, AD; Rouse, DJ; Lopes, V; Hughes, BL
Published in: Obstet Gynecol
July 2015

OBJECTIVE: To evaluate whether exposure to 17α-hydroxyprogesterone caproate is associated with the rate of peripartum infection in women who deliver preterm and their neonates. METHODS: This is a retrospective cohort study of patients who delivered before 37 weeks of gestation at a tertiary care hospital between July 1, 2005, and December 31, 2012. Women in the case group (women exposed to 17α-hydroxyprogesterone caproate) were matched to women in a control group (unexposed patients) by gestational age and delivery date. The primary outcome was a composite infection rate comprising histologic or clinical chorioamnionitis, endometritis, or early-onset neonatal sepsis. To detect a 15% difference in composite infection rate between women exposed to 17α-hydroxyprogesterone caproate and those unexposed (two-tailed α=0.05 and power=80%), 183 patients per group were required. Logistic regression was performed to control for a history of prior spontaneous preterm birth and exposure to betamethasone. RESULTS: The primary outcome frequency for women exposed to 17α-hydroxyprogesterone caproate was 34.6% (64 patients) compared with 33% (61 patients) in those unexposed (P=.74). There was no significant difference between women exposed to 17α-hydroxyprogesterone caproate and those unexposed in frequency of clinical chorioamnionitis (1.9% compared with 1.1%, P=.66), histologic chorioamnionitis (39.4% compared with 40%, P=.92), or early-onset neonatal sepsis (2.7% compared with 1.1%, P=.28). A total of 7.1% of women exposed to 17α-hydroxyprogesterone caproate developed endometritis compared with 2.7% of those unexposed (P=.05). The adjusted odds ratio for the primary outcome in women exposed to 17α-hydroxyprogesterone caproate was 0.65 (95% confidence interval 0.31-1.38). CONCLUSION: Exposure to 17α-hydroxyprogesterone caproate does not increase the risk of peripartum infection among women who deliver preterm or their neonates. LEVEL OF EVIDENCE: II.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Obstet Gynecol

DOI

EISSN

1873-233X

Publication Date

July 2015

Volume

126

Issue

1

Start / End Page

103 / 108

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sepsis
  • Risk Factors
  • Retrospective Studies
  • Progestins
  • Premature Birth
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Logistic Models
  • Infant, Newborn
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mainiero, A. D., Rouse, D. J., Lopes, V., & Hughes, B. L. (2015). Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection. Obstet Gynecol, 126(1), 103–108. https://doi.org/10.1097/AOG.0000000000000881
Mainiero, Alexandra D., Dwight J. Rouse, Vrishali Lopes, and Brenna L. Hughes. “Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.Obstet Gynecol 126, no. 1 (July 2015): 103–8. https://doi.org/10.1097/AOG.0000000000000881.
Mainiero AD, Rouse DJ, Lopes V, Hughes BL. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection. Obstet Gynecol. 2015 Jul;126(1):103–8.
Mainiero, Alexandra D., et al. “Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.Obstet Gynecol, vol. 126, no. 1, July 2015, pp. 103–08. Pubmed, doi:10.1097/AOG.0000000000000881.
Mainiero AD, Rouse DJ, Lopes V, Hughes BL. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection. Obstet Gynecol. 2015 Jul;126(1):103–108.

Published In

Obstet Gynecol

DOI

EISSN

1873-233X

Publication Date

July 2015

Volume

126

Issue

1

Start / End Page

103 / 108

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sepsis
  • Risk Factors
  • Retrospective Studies
  • Progestins
  • Premature Birth
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Logistic Models
  • Infant, Newborn